Opinion|Videos|February 18, 2025
Adoption of New Treatments for BCG-Unresponsive NMIBC
Author(s)Mark D. Tyson, II, MD, MPH
A panelist discusses how the ability to administer newer non–muscle-invasive bladder cancer (NMIBC) treatments in local urology practices rather than specialized oncology centers reduces patient burden and travel requirements while suggesting that increased education and support could help more health care providers adopt these treatment options.
Advertisement
Episodes in this series
- From an operational standpoint, how important is it that these treatments can be administered by urologists locally, without the need to refer patients to oncology centers? Please discuss the overall burden on patients, systemic adverse effects, and the need to travel to specialized centers.
- What strategies would you recommend to encourage more health care practitioners to adopt newer treatment modalities for BCG-unresponsive NMIBC?
Advertisement
Related to this article
Butterfly Medical has also submitted a premarket approval application to the FDA.
Moderators and participants reviewed ARANOTE, ARACOG, and ARASEC data and how they inform individualized treatment for mCSPC.
Timothy N. Clinton, MD, recaps bladder cancer data from the 2026 AUA Northeastern Section meeting, including BOND-003 cretostimogene results and safety data on mitomycin intravesical solution.
Juan J. Andino, MD, MBA, discusses surgical decision-making in prolonged ischemic priapism and how ischemia duration affects erectile dysfunction risk and treatment timing.
Jack R. Andrews, MD, discusses BED-PSMA-411 findings comparing PSMA-PET detection rates and urinary excretion in prostate cancer biochemical recurrence.
Sandip Prasad, MD, MPhil, discusses ENVISION trial findings on mitomycin for intravesical solution and patient selection in clinical practice.
OpenFlo incorporates a design that modifies key mechanical features of conventional Foley catheters.
Study design discussions can help patients weigh personalized marketing claims, according to Jean Cunningham, PharmD, BCPS.
Advertisement
Advertisement
Trending on Urology Times
1
Study compares PSMA-PET radiopharmaceuticals in prostate cancer recurrence
2
Butterfly Prostatic Retraction Device granted EU MDR certification for BPH
3
Variation in PSMA PET Adoption for Prostate Cancer Care
4
Matching mCSPC treatment to the patient, not just the trial data
5